Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -36.19% is 31% above its 5-year average of -52.41%, near the high end of its 5-year range (-108.69%–-27.15%).
9.12% below its 12-month average of -33.16%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.40%.
RETURN ON ASSETS (ROA)
-36.19%
RETURN ON ASSETS (ROA) AVG TTM
-33.16%
RETURN ON ASSETS (ROA) AVG 3Y
-60.79%
RETURN ON ASSETS (ROA) AVG 5Y
-52.41%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.12%
CURRENT VS 3Y AVG
+40.47%
CURRENT VS 5Y AVG
+30.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-12.16%
vs the sector median at left
Tectonic Therapeutic, Inc.
Market Cap
$422.86M
Return on Assets (ROA)
-36.19%
TTM Avg
-33.16%
3Y Avg
-60.79%
5Y Avg
-52.41%
Market Cap
$422.72M
Return on Assets (ROA)
-6.40%
TTM Avg
-54.29%
3Y Avg
-36.81%
5Y Avg
-26.71%
Market Cap
$424.10M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$419.87M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$426.51M
Return on Assets (ROA)
-86.35%
TTM Avg
-25.00%
3Y Avg
-21.41%
5Y Avg
-20.43%
Market Cap
$418.95M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$416.27M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
Market Cap
$415.98M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$431.97M
Return on Assets (ROA)
-19.71%
TTM Avg
-24.50%
3Y Avg
-30.22%
5Y Avg
-31.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $422.86M | -36.19% | -33.16% | -60.79% | -52.41% |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -6.40% | -54.29% | -36.81% | -26.71% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -3.84% | -6.38% | -6.57% | -4.38% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -14.54% | -48.52% | -33.40% | -26.00% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -86.35% | -25.00% | -21.41% | -20.43% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | -31.15% | -77.61% | -57.20% | -46.24% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -61.86% | -66.50% | -24.17% | -122.74% |
| Rezolute, Inc. (RZLT)vs › | $415.98M | -68.75% | -55.58% | -51.15% | -46.76% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -19.71% | -24.50% | -30.22% | -31.88% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | -62.39% | -45.13% | -56.85% | -56.85% |
ROA
-36.2%
ROE
-38.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -28.41% |
| 2024-12-31 | -37.92% |
| 2023-12-31 | -108.69% |
| 2022-12-31 | -68.16% |
| 2021-12-31 | -27.15% |
| 2020-12-31 | -44.14% |
| 2019-12-31 | -36.39% |
| 2018-12-31 | -34.73% |
| 2017-12-31 | -265.57% |
| 2016-12-31 | -86.37% |
